Navigation Links
Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings
Date:4/25/2011

MINNETONKA, Minn., April 25, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of clinical studies using Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products are scheduled to be presented at three upcoming professional meetings.  The meetings include the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in Washington DC, May 1 - 4; the American Urological Association (AUA) Annual Meeting in Washington DC, May 14 -17; and the American Society of Colon & Rectal Surgeons (ASCRS) Annual Meeting in Vancouver, Canada, May 14 -18.  

"There is a growing body of clinical evidence in support of our Urgent PC and Macroplastique products," said David Kaysen, President and CEO of Uroplasty.  "This new data, along with previously published studies, confirms the efficacy and safety of both our products for the treatment of patients who suffer daily with overactive bladder or stress urinary incontinence."  

ACOG Presentations

  • Percutaneous Tibial Nerve Stimulation vs. Validated Sham in those Exposed to Pharmacologic Therapy presented by Dr. Denise Elser, Illinois Urogynecology, Oak Lawn, IL
  • Percutaneous Tibial Nerve Stimulation (PTNS) and the Effect on Fecal Incontinence* presented by Dr. Craig McCoy, Central Missouri Women's Healthcare, Marshall, MO

  • AUA Presentations

  • Insight into Percutaneous Tibial Nerve Stimulation: Critical Evaluation of the SUmiT Trial presented by Dr. Kenneth M. Peters, Beaumont Hospital, Royal Oak, MI
  • Long-term Durability of Polydimethylsiloxane Injection for Female Stress Urinary Incontinence Correlates with Histopathology presented by Dr. Gamal Ghoniem, Cleveland Clinic, Weston, FL
  • Treatment Interval Frequency of Percutaneous Tibial Nerve Stimulation: Preliminary Results from the STEP study presented by Dr. Scott A. MacDiarmid, Alliance Urology Specialists, Greensboro, NC

  • ASCRS Presentations

  • Percutaneous Tibial Nerve Stimulation and Effect on Fecal Incontinence: Results from Two Recent Overactive Bladder Trials* presented by Dr. Steven Siegel, Metro Urology, Woodbury, MN.  
  • A Prospective, Single-Blinded, Placebo-Controlled Study into the Role of Percutaneous and Transcutaneous Tibial Nerve Stimulation for Fecal Incontinence* presented by Dr. Anil George, St. Mark's Hospital, London, UK
  • Predictive Factors for Percutaneous Tibial Nerve Stimulation for Fecal Incontinence* presented by Dr. Anil George, St. Mark's Hospital, London

  • * Fecal incontinence is not currently an FDA cleared indication for PTNS in the U.S.

    About Uroplasty Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence.  We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.  For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

    Safe HarborThis press release contains forward-looking statements that reflect our best estimates regarding future events that could affect our financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report and on Form 10-K filed with the SEC.  We cannot be certain that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.Company Contact:Investor Relations Contacts:Media Contact:Uroplasty, Inc.

    EVC Group, Inc.

    EVC Group, Inc.David Kaysen, CEO

    Doug Sherk/Jenifer Kirtland

    Chris Gale/ Steve DiMattia(952) 426-6140

    (415) 896-2005

    (646) 201-5431dave.kaysen@uroplasty.com

    dsherk@evcgroup.com

    cgale@evcgroup.comjkirtland@evcgroup.com

    sdimattia@evcgroup.com
    '/>"/>

    SOURCE Uroplasty, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
    6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
    8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
    9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
    10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
    (Date:5/19/2016)... , May 19, 2016 , The ... (a bstract # 8006)   The ... of the treated patients with 90% of the ... six months or more . Seventy two percent of the patients had ... (MSE:PHM) announces the positive results from a Phase I study of plitidepsin in ...
    (Date:5/19/2016)... NEW YORK , May 19, 2016 ... one sector that is always abounding of surprises is without ... the Healthcare sector ahead of today,s trading session: Alkermes PLC ... AMAG ), IDEXX Laboratories Inc. (NASDAQ: IDXX ... Sign up for your complimentary alerts at: ...
    Breaking Medicine Technology:
    (Date:5/23/2016)... Bensonhurst, NY (PRWEB) , ... May 23, 2016 , ... ... Enrico Ferdico took the time to summarize the weight loss process: , New patients ... a Body Composition Analysis (BCA) to get accurately evaluated. , Body Composition Analysis, There ...
    (Date:5/23/2016)... , ... May 23, 2016 , ... According to an article published May ... massive role in oral health and hygiene. The article points out that, as long as ... their toothbrushes will become worn and frayed. Of course, these worn-out bristles won’t clean teeth ...
    (Date:5/23/2016)... , ... May 23, 2016 , ... According to an ... in an exuberant mood since the birth of her son, Rockwell Lloyd Liu, and ... ever had.” The “Elementary” and “Kill Bill” star explains that, as a career oriented ...
    (Date:5/23/2016)... ... May 23, 2016 , ... The Clinical Data ... from the Japan PMDA, US FDA, industry and academia at the 2016 ... format data from clinical trials so that it can be shared and compared, ...
    (Date:5/23/2016)... ... ... NYDNRehab, a New York City-based physical therapy clinic , is introducing ... type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of University ... With over 10 million sport injuries per year in the United States, ...
    Breaking Medicine News(10 mins):